Publications

1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis

Authors: AR Clamp, I McNeish, D Radice, R Lord, A Michael, A Cook, R Agarwal, A Walt...

E-pub date: 1 Sep 2025

Journal name: Annals of Oncology

1145P DNA-repair patterns (DRP) and immune contexture define durable benefit for BRCA2-deficient high-grade serous carcinoma (HGSC) in a national genomic study

Authors: IG Funingana, J Ambrose, L Porcu, P Smith, AA Sosinsky, JD Brenton

E-pub date: 1 Sep 2025

Journal name: Annals of Oncology

A pathway toward clinical translation of hyperpolarized [1,4-13C2,2,3-d2]fumarate as an imaging biomarker for early cellular necrosis in vivo.

Authors: JR Birchall, P Wodtke, A Grimmer, ESS Hansen, LB Bertelsen, N Bøgh, M Wylo...

E-pub date: 1 Sep 2025

Journal name: Magn Reson Med

Figure S8 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Authors: CYC Lee, I Dean, N Richoz, Z Li, BC Kennedy, LA Vettore, Y Samarakoon, KL G...

E-pub date: 1 Sep 2025

Journal name:

Figure S6 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Authors: CYC Lee, I Dean, N Richoz, Z Li, BC Kennedy, LA Vettore, Y Samarakoon, KL G...

E-pub date: 1 Sep 2025

Journal name:

Figure S3 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Authors: CYC Lee, I Dean, N Richoz, Z Li, BC Kennedy, LA Vettore, Y Samarakoon, KL G...

E-pub date: 1 Sep 2025

Journal name:

Binding of heterochromatin protein Rhino to a subset of piRNA clusters depends on a combination of two histone marks.

Authors: A Akkouche, E Kneuss, S Bornelöv, Y Renaud, EL Eastwood, J van Lopik, N Gu...

E-pub date: 31 Aug 2025

Journal name: Nat Struct Mol Biol

Retraction Note: Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis.

Authors: Z Luo, M Xia, W Shi, C Zhao, J Wang, D Xin, X Dong, Y Xiong, F Zhang, K Ber...

E-pub date: 31 Aug 2025

Journal name: Nature

Filters

Research Groups

Core Facilities

Start date

End date

1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis

1145P DNA-repair patterns (DRP) and immune contexture define durable benefit for BRCA2-deficient high-grade serous carcinoma (HGSC) in a national genomic study

A pathway toward clinical translation of hyperpolarized [1,4-13C2,2,3-d2]fumarate as an imaging biomarker for early cellular necrosis in vivo.

Figure S8 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Figure S6 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Figure S3 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Binding of heterochromatin protein Rhino to a subset of piRNA clusters depends on a combination of two histone marks.

Retraction Note: Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis

1145P DNA-repair patterns (DRP) and immune contexture define durable benefit for BRCA2-deficient high-grade serous carcinoma (HGSC) in a national genomic study

A pathway toward clinical translation of hyperpolarized [1,4-13C2,2,3-d2]fumarate as an imaging biomarker for early cellular necrosis in vivo.

Figure S8 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Figure S6 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Figure S3 from In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade

Binding of heterochromatin protein Rhino to a subset of piRNA clusters depends on a combination of two histone marks.

Retraction Note: Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis.